David Cibula1, Richard Pötter2, François Planchamp3, Elisabeth Avall-Lundqvist4, Daniela Fischerova5, Christine Haie Meder6, Christhardt Köhler7, Fabio Landoni8, Sigurd Lax9, Jacob Christian Lindegaard10, Umesh Mahantshetty11, Patrice Mathevet12, W Glenn McCluggage13, Mary McCormack14, Raj Naik15, Remi Nout16, Sandro Pignata17, Jordi Ponce18, Denis Querleu3, Francesco Raspagliesi19, Alexandros Rodolakis20, Karl Tamussino21, Pauline Wimberger22, Maria Rosaria Raspollini23. 1. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Electronic address: dc@davidcibula.cz. 2. Department of Radiotherapy, Medical University of Vienna, Austria. 3. Institut Bergonié, Bordeaux, France. 4. Linkoping University, Sweden. 5. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 6. Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France. 7. Asklepios Hambourg Altona and University of Cologne, Medical Faculty, Department of Gynecology, Germany. 8. University of Milan Bicocca, Monza, Italy. 9. General Hospital Graz Sued-West, Austria. 10. Department of Oncology, Aarhus University, Denmark. 11. Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India. 12. Lausanne University, Switzerland. 13. Department of Pathology, Belfast Health and Social Care Trust, United Kingdom. 14. University College Hospital London, United Kingdom. 15. Queen Elizabeth Hospital, Gateshead, United Kingdom. 16. Department of Radiation Oncology, Leiden University, The Netherlands. 17. Istituto Nazionale per lo Studio e la Cura dei Tumori "FondazioneG Pascale," IRCCS, Naples, Italy. 18. University Hospital of Bellvitge (IDIBELL), Barcelona, Spain. 19. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 20. Athens University, Greece. 21. Medical University of Graz, Austria. 22. Dresden University, TU Dresden, Germany. 23. University Hospital, Careggi, Florence, Italy.
Abstract
BACKGROUND: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
BACKGROUND: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
Authors: Danielle Rodin; Emily A Burger; Rifat Atun; Michael Barton; Mary Gospodarowicz; Surbhi Grover; Timothy P Hanna; David A Jaffray; Felicia M Knaul; Yolande Lievens; Eduardo Zubizarreta; Michael Milosevic Journal: Lancet Oncol Date: 2019-05-28 Impact factor: 41.316
Authors: A Martinez; M Voglimacci; A Lusque; A Ducassou; L Gladieff; N Dupuis; M A Angeles; C Martinez; Y Tanguy Le Gac; E Chantalat; A Hitzel; F Courbon; G Ferron; E Gabiache Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-08 Impact factor: 9.236
Authors: Benny Brandt; Vasileios Sioulas; Derman Basaran; Theresa Kuhn; Katherine LaVigne; Ginger J Gardner; Yukio Sonoda; Dennis S Chi; Kara C Long Roche; Jennifer J Mueller; Elizabeth L Jewell; Vance A Broach; Oliver Zivanovic; Nadeem R Abu-Rustum; Mario M Leitao Journal: Gynecol Oncol Date: 2020-01-07 Impact factor: 5.482
Authors: Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Ryuji Hamamoto; Jun Itami Journal: In Vivo Date: 2019 Sep-Oct Impact factor: 2.155
Authors: Menelaos Tzafetas; Anita Mitra; Maria Paraskevaidi; Zsolt Bodai; Ilkka Kalliala; Sarah Bowden; Konstantinos Lathouras; Francesca Rosini; Marcell Szasz; Adele Savage; Julia Balog; James McKenzie; Deirdre Lyons; Phillip Bennett; David MacIntyre; Sadaf Ghaem-Maghami; Zoltan Takats; Maria Kyrgiou Journal: Proc Natl Acad Sci U S A Date: 2020-03-16 Impact factor: 11.205
Authors: Ester P Olthof; Maaike A van der Aa; Judit A Adam; Lukas J A Stalpers; Hans H B Wenzel; Jacobus van der Velden; Constantijne H Mom Journal: Int J Clin Oncol Date: 2021-07-09 Impact factor: 3.402